Financial PositionCytokinetics ended the quarter with $1.04B in cash and cash equivalents, providing a strong financial position.
Regulatory ApprovalManagement believes they're aligned with FDA following a collaborative meeting and quick turnaround on updated submission, emphasizing aficamten's intrinsic properties should enable a differentiated position.
Sales And Market ReadinessCytokinetics has hired a salesforce with deep existing cardiovascular experience, indicating strong commercial readiness activities in the U.S.